Colony formation assays indicated a higher number of clones in HER2-positive breast cancer cells treated with both trastuzumab and 13(S)-HODE (Supplementary figure 6C), the results were also consistent with the treatment with pyrotinib (Supplementary figure 6D) and lapatinib (Supplementary figure 6E). The gene discussed is ERBB2; the disease is breast cancer.